Human Acellular Dermal Wound Matrix: Evidence and Experience

Overview

Journal Int Wound J

Specialties Emergency Medicine
Orthopedics

Date 2013 Nov 29

PMID 24283346

Citations 35

Authors

Robert S Kirsner

Greg Bohn

Vickie R Driver

Joseph L Mills Sr

Lillian B Nanney

Marie L Williams

Stephanie C Wu

Affiliations

Soon will be listed here.

Abstract

A chronic wound fails to complete an orderly and timely reparative process and places patients at increased risk for wound complications that negatively impact quality of life and require greater health care expenditure. The role of extracellular matrix (ECM) is critical in normal and chronic wound repair. Not only is ECM the largest component of the dermal skin layer, but also ECM proteins provide structure and cell signalling that are necessary for successful tissue repair. Chronic wounds are characterised by their inflammatory and proteolytic environment, which degrades the ECM. Human acellular dermal matrices, which provide an ECM scaffold, therefore, are being used to treat chronic wounds. The ideal human acellular dermal wound matrix (HADWM) would support regenerative healing, providing a structure that could be repopulated by the body's cells. Experienced wound care investigators and clinicians discussed the function of ECM, the evidence related to a specific HADWM (Graftjacket(®) regenerative tissue matrix, Wright Medical Technology, Inc., licensed by KCI USA, Inc., San Antonio, TX), and their clinical experience with this scaffold. This article distills these discussions into an evidence-based and practical overview for treating chronic lower extremity wounds with this HADWM.

Citing Articles

Decellularized extracellular matrix for organoid and engineered organ culture.

Guo X, Liu B, Zhang Y, Cheong S, Xu T, Lu F J Tissue Eng. 2024; 15:20417314241300386.

PMID: 39611117 PMC: 11603474. DOI: 10.1177/20417314241300386.

Conventional Versus Regenerative Methods for Wound Healing: A Comparative Experimental Study on a Sheep Model.

Elia R, Maruccia M, di Summa P, Trisciuzzi R, Lovero G, Cazzato G Medicina (Kaunas). 2024; 60(11).

PMID: 39597021 PMC: 11596313. DOI: 10.3390/medicina60111836.

Dissolvable microneedle-based wound dressing transdermally and continuously delivers anti-inflammatory and pro-angiogenic exosomes for diabetic wound treatment.

Cao Y, Chen B, Liu Q, Mao Y, He Y, Liu X Bioact Mater. 2024; 42:32-51.

PMID: 39280578 PMC: 11399477. DOI: 10.1016/j.bioactmat.2024.08.016.

The Myofibroblast Fate of Therapeutic Mesenchymal Stromal Cells: Regeneration, Repair, or Despair?.

Younesi F, Hinz B Int J Mol Sci. 2024; 25(16).

PMID: 39201399 PMC: 11354465. DOI: 10.3390/ijms25168712.

Surgical correction of facial bone deformity and enophthalmos after tripod fracture using an acellular dermal matrix: a case report.

Choi W, Kim J, Cheon J, Yang J Arch Craniofac Surg. 2024; 25(5):252-256.

PMID: 39175194 PMC: 11540491. DOI: 10.7181/acfs.2024.00066.

References

Steed D, Donohoe D, Webster M, Lindsley L . Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg. 1996; 183(1):61-4. View

Brigido S, Boc S, Lopez R . Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics. 2004; 27(1 Suppl):s145-9. DOI: 10.3928/0147-7447-20040102-14. View

Sheehan P, Jones P, Giurini J, Caselli A, Veves A . Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg. 2006; 117(7 Suppl):239S-244S. DOI: 10.1097/01.prs.0000222891.74489.33. View

Wainwright D . Use of an acellular allograft dermal matrix (AlloDerm) in the management of full-thickness burns. Burns. 1995; 21(4):243-8. DOI: 10.1016/0305-4179(95)93866-i. View

Marston W, Hanft J, Norwood P, Pollak R . The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003; 26(6):1701-5. DOI: 10.2337/diacare.26.6.1701. View

Lavery L, Armstrong D, Harkless L . Classification of diabetic foot wounds. Ostomy Wound Manage. 1997; 43(2):44-8, 50, 52-3. View

Harrington C, Zagari M, Corea J, Klitenic J . A cost analysis of diabetic lower-extremity ulcers. Diabetes Care. 2000; 23(9):1333-8. DOI: 10.2337/diacare.23.9.1333. View

Brem H, Stojadinovic O, Diegelmann R, Entero H, Lee B, Pastar I . Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med. 2007; 13(1-2):30-9. PMC: 1869625. DOI: 10.2119/2006-00054.Brem. View

Reyzelman A, Crews R, Moore J, Moore L, Mukker J, Offutt S . Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J. 2009; 6(3):196-208. PMC: 7951349. DOI: 10.1111/j.1742-481X.2009.00585.x. View

10.

Driver V, Fabbi M, Lavery L, Gibbons G . The costs of diabetic foot: the economic case for the limb salvage team. J Vasc Surg. 2010; 52(3 Suppl):17S-22S. DOI: 10.1016/j.jvs.2010.06.003. View

11.

Girod I, Valensi P, LAFORET C, Moreau-Defarges T, Guillon P, Baron F . An economic evaluation of the cost of diabetic foot ulcers: results of a retrospective study on 239 patients. Diabetes Metab. 2003; 29(3):269-77. DOI: 10.1016/s1262-3636(07)70036-8. View

12.

Martin B, Sangalang M, Wu S, Armstrong D . Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience. Int Wound J. 2006; 2(2):161-5. PMC: 7951241. DOI: 10.1111/j.1742-4801.2005.00099.x. View

13.

Menon N, Rodriguez E, Byrnes C, Girotto J, Goldberg N, Silverman R . Revascularization of human acellular dermis in full-thickness abdominal wall reconstruction in the rabbit model. Ann Plast Surg. 2003; 50(5):523-7. DOI: 10.1097/01.SAP.0000044252.76804.6B. View

14.

Singer A, Clark R . Cutaneous wound healing. N Engl J Med. 1999; 341(10):738-46. DOI: 10.1056/NEJM199909023411006. View

15.

Wu S, Driver V, Wrobel J, Armstrong D . Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag. 2007; 3(1):65-76. PMC: 1994045. View

16.

Ennis W, Meneses P . Managing wounds in a managed care environment: the integration concept. Ostomy Wound Manage. 1999; 44(11):22-6, 28-31, 34-6, passim. View

17.

Mast B, Schultz G . Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 1996; 4(4):411-20. DOI: 10.1046/j.1524-475X.1996.40404.x. View

18.

Nelson C, Bissell M . Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2006; 22:287-309. PMC: 2933192. DOI: 10.1146/annurev.cellbio.22.010305.104315. View

19.

Mulder G, Vande Berg J . Cellular senescence and matrix metalloproteinase activity in chronic wounds. Relevance to debridement and new technologies. J Am Podiatr Med Assoc. 2002; 92(1):34-7. DOI: 10.7547/87507315-92-1-34. View

20.

Bornstein P, Sage E . Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol. 2002; 14(5):608-16. DOI: 10.1016/s0955-0674(02)00361-7. View